ArticleFrontiers in medicine2026
Acquired reactive perforating collagenosis in a patient with multiple comorbidities: a case report from Palestine.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Perforating dermatoses comprise a heterogeneous group of skin disorders characterized by transepidermal elimination of dermal components such as collagen, elastic fibers, or fibrin, resulting in pruritic papulonodular lesions. Four established subtypes are identified: reactive perforating collagenosis (RPC), elastosis perforans serpiginosa, perforating folliculitis, and Kyrle disease. RPC can be hereditary, manifesting in childhood, or acquired (ARPC), which generally develops in maturity and is closely associated with systemic diseases, particularly chronic renal failure and diabetes mellitus. Case presentation: A 55-year-old male who presented with symptoms of decompensated heart failure, type-2 diabetes, chronic renal failure, and hyperparathyroidism. During hospitalization, he complained of cutaneous pruritus and skin lesions all over his body. Physical examination revealed papules of varying sizes; some progressed into umbilicated nodules featuring central keratotic plugs. Histopathology revealed cup-shaped epidermal invaginations with necrotic debris and transepidermal extrusion of modified collagen, as confirmed by Masson's trichrome stain (MTS). Therefore, a diagnosis of ARPC was established for the first time. Intervention and outcome: The patient was treated with the Dermovate scalp application, S.C. omalizumab administered monthly, fexofenadine hydrochloride, and body moisturizers. Besides that, treatment for glucose control, fluid overload, and recovery of renal function was also applied. Following up after 1 month revealed minimal improvement in pruritus; however, there was no change in skin lesion status. Conclusion: Acquired reactive perforating collagenosis remains a rare dermatologic disease. To the best of our knowledge, this represents the first reported case from Palestine. This case highlights the potential coexistence of ARPC with various systemic comorbidities, underscoring the need for comprehensive clinical assessment and exploration of underlying diseases in affected individuals. Furthermore, it highlights the importance of increased clinical awareness, particularly among physicians in similar settings, to consider ARPC in the differential diagnosis of pruritic cutaneous eruptions, especially in patients with associated comorbidities such as diabetes mellitus and chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.